In intermediate-risk breast cancer, postmastectomy chest-wall irradiation did not improve 10-year overall survival as compared with no chest-wall irradiation. Full SUPREMO phase 3 trial results and Research Summary: nej.md/3Jxd3sI
#MedSky #Oncology
#MedSky #Oncology
November 8, 2025 at 2:01 PM
In intermediate-risk breast cancer, postmastectomy chest-wall irradiation did not improve 10-year overall survival as compared with no chest-wall irradiation. Full SUPREMO phase 3 trial results and Research Summary: nej.md/3Jxd3sI
#MedSky #Oncology
#MedSky #Oncology
Guideline Update: Postmastectomy Radiation Therapy Boosts Survival for Node-Positive and Selected Node-Negative Breast Cancer Patients.
by Jimenez RB, Abdou Y (...) Horst KC et 17 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-01747
by Jimenez RB, Abdou Y (...) Horst KC et 17 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-01747
October 29, 2025 at 4:39 AM
Guideline Update: Postmastectomy Radiation Therapy Boosts Survival for Node-Positive and Selected Node-Negative Breast Cancer Patients.
by Jimenez RB, Abdou Y (...) Horst KC et 17 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-01747
by Jimenez RB, Abdou Y (...) Horst KC et 17 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-01747
Bolus Use in Postmastectomy Radiation Therapy for Breast Cancer: A Systematic Literature Review
@tcrtcancer.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#3Dprinting #radiotherapy #radonc #oncology #oncsky #cancertreatment #openaccess
@tcrtcancer.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#3Dprinting #radiotherapy #radonc #oncology #oncsky #cancertreatment #openaccess
June 20, 2025 at 8:49 PM
Bolus Use in Postmastectomy Radiation Therapy for Breast Cancer: A Systematic Literature Review
@tcrtcancer.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#3Dprinting #radiotherapy #radonc #oncology #oncsky #cancertreatment #openaccess
@tcrtcancer.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#3Dprinting #radiotherapy #radonc #oncology #oncsky #cancertreatment #openaccess
New guidelines provide recommendations on the use of postmastectomy radiation therapy in patients with #breastcancer. From @ascopost.bsky.social and @annsurgoncology.bsky.social.
https://bit.ly/4nQpz5e
#bcsm #BreastCancerAwarenessMonth #BCAM
https://bit.ly/4nQpz5e
#bcsm #BreastCancerAwarenessMonth #BCAM
October 14, 2025 at 4:40 PM
New guidelines provide recommendations on the use of postmastectomy radiation therapy in patients with #breastcancer. From @ascopost.bsky.social and @annsurgoncology.bsky.social.
https://bit.ly/4nQpz5e
#bcsm #BreastCancerAwarenessMonth #BCAM
https://bit.ly/4nQpz5e
#bcsm #BreastCancerAwarenessMonth #BCAM
📌Does Postmastectomy Radiotherapy in 'Intermediate-Risk' Breast Cancer Impact Overall Survival?
👉🏻10-Year Results of the BIG 2-04 MRC SUPREMO Randomized Trial: On Behalf of the SUPREMO Trial Investigators by Prof Ian Kunkler
#SABCS24 #day3 @oncoalert.bsky.social #OncoAlertAF #GeneralSession2
👉🏻10-Year Results of the BIG 2-04 MRC SUPREMO Randomized Trial: On Behalf of the SUPREMO Trial Investigators by Prof Ian Kunkler
#SABCS24 #day3 @oncoalert.bsky.social #OncoAlertAF #GeneralSession2
December 12, 2024 at 4:17 PM
📌Does Postmastectomy Radiotherapy in 'Intermediate-Risk' Breast Cancer Impact Overall Survival?
👉🏻10-Year Results of the BIG 2-04 MRC SUPREMO Randomized Trial: On Behalf of the SUPREMO Trial Investigators by Prof Ian Kunkler
#SABCS24 #day3 @oncoalert.bsky.social #OncoAlertAF #GeneralSession2
👉🏻10-Year Results of the BIG 2-04 MRC SUPREMO Randomized Trial: On Behalf of the SUPREMO Trial Investigators by Prof Ian Kunkler
#SABCS24 #day3 @oncoalert.bsky.social #OncoAlertAF #GeneralSession2
Postmastectomy implant-based breast reconstruction is associated with an increased risk of both B-cell and T-cell non-Hodgkin lymphomas, though the absolute risk remains very low. doi.org/g9w5k9
Implant-based reconstruction linked to increased risk of breast lymphomas
Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell non-Hodgkin lymphoma histologies.
medicalxpress.com
August 15, 2025 at 10:40 AM
Postmastectomy implant-based breast reconstruction is associated with an increased risk of both B-cell and T-cell non-Hodgkin lymphomas, though the absolute risk remains very low. doi.org/g9w5k9
Development and Validation of Prediction Models for Sentinel Lymph Node Status Indicating Postmastectomy Radiotherapy in Breast Cancer: a Population-Based Study of 18 185 Women https://www.medrxiv.org/content/10.1101/2024.02.21.24303165v1
Development and Validation of Prediction Models for Sentinel Lymph Node Status Indicating Postmastectomy Radiotherapy in Breast Cancer: a Population-Based Study of 18 185 Women https://www.medrxiv.org/content/10.1101/2024.02.21.24303165v1
Background: Postmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast reconstructio
www.medrxiv.org
February 25, 2024 at 7:16 AM
Development and Validation of Prediction Models for Sentinel Lymph Node Status Indicating Postmastectomy Radiotherapy in Breast Cancer: a Population-Based Study of 18 185 Women https://www.medrxiv.org/content/10.1101/2024.02.21.24303165v1
Three leading cancer organizations @ascocancer.bsky.social, @astro-org.bsky.social, & @socsurgonc.bsky.social updated guidelines on postmastectomy radiotherapy based on new evidence.
Expert panel co-chaired by Rachel B. Jimenez, MD & Kathleen C. Horst, MD
ascopost.com/news/septemb...
Expert panel co-chaired by Rachel B. Jimenez, MD & Kathleen C. Horst, MD
ascopost.com/news/septemb...
September 22, 2025 at 3:59 PM
Three leading cancer organizations @ascocancer.bsky.social, @astro-org.bsky.social, & @socsurgonc.bsky.social updated guidelines on postmastectomy radiotherapy based on new evidence.
Expert panel co-chaired by Rachel B. Jimenez, MD & Kathleen C. Horst, MD
ascopost.com/news/septemb...
Expert panel co-chaired by Rachel B. Jimenez, MD & Kathleen C. Horst, MD
ascopost.com/news/septemb...
A team from Medical College of Wisconsin in Milwaukee also found that transgender women are less likely to receive endocrine therapy for hormone receptor (HR)-positive breast cancers and postmastectomy breast reconstruction #radiology #DCIS #breastcancer #LGBTQ+
Trans, gender-diverse patients more likely to be diagnosed with DCIS
Transgender and gender-diverse breast cancer patients are more likely to be diagnosed with DCIS and less likely to receive treatment.
buff.ly
May 23, 2025 at 2:10 PM
A team from Medical College of Wisconsin in Milwaukee also found that transgender women are less likely to receive endocrine therapy for hormone receptor (HR)-positive breast cancers and postmastectomy breast reconstruction #radiology #DCIS #breastcancer #LGBTQ+
Breast cancer patients who undergo premastectomy radiation therapy and immediate microsurgical breast reconstruction experience similar complication rates as those with postmastectomy rad...
🧵 Thread below
Full analysis: https://helixbrief.com/article/f0389ed6-70a0-4c8f-86e7-dfdb016d92af
🧵 Thread below
Full analysis: https://helixbrief.com/article/f0389ed6-70a0-4c8f-86e7-dfdb016d92af
October 23, 2025 at 10:45 PM
Breast cancer patients who undergo premastectomy radiation therapy and immediate microsurgical breast reconstruction experience similar complication rates as those with postmastectomy rad...
🧵 Thread below
Full analysis: https://helixbrief.com/article/f0389ed6-70a0-4c8f-86e7-dfdb016d92af
🧵 Thread below
Full analysis: https://helixbrief.com/article/f0389ed6-70a0-4c8f-86e7-dfdb016d92af
Ten-year study on breast cancer (pT1N1, pT2N1, pT3N0, or pT2N0/grade 3) found postmastectomy irradiation’s role in survival is uncertain. PMID:41191939, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2412225 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2412225
No description available
doi.org
November 27, 2025 at 12:10 PM
Featured today by @MSKLibrary: Age Impacts Clinical and Patient-Reported Outcomes following Postmastectomy Breast Reconstruction dx.doi.org/10.1097/PRS....
#BreastReconstruction #PostMastectomy
#PatientReportedOutcomes #BreastCancerRecovery
#ReconstructiveSurgery #PlasticSurgeryOutcomes
#BreastReconstruction #PostMastectomy
#PatientReportedOutcomes #BreastCancerRecovery
#ReconstructiveSurgery #PlasticSurgeryOutcomes
Age Impacts Clinical and Patient-Reported Outcomes... : Plastic and Reconstructive Surgery
d patient-reported outcomes (PROs) using the BREAST-Q longitudinally 5 years after postmastectomy breast reconstruction.
Methods:
The authors conducted a retrospective analysis of patients who unde...
dx.doi.org
May 27, 2025 at 5:25 PM
Featured today by @MSKLibrary: Age Impacts Clinical and Patient-Reported Outcomes following Postmastectomy Breast Reconstruction dx.doi.org/10.1097/PRS....
#BreastReconstruction #PostMastectomy
#PatientReportedOutcomes #BreastCancerRecovery
#ReconstructiveSurgery #PlasticSurgeryOutcomes
#BreastReconstruction #PostMastectomy
#PatientReportedOutcomes #BreastCancerRecovery
#ReconstructiveSurgery #PlasticSurgeryOutcomes
#Breastcancer outcomes after NSM in #BRCA pathogenic mutation carriers vs. non-BRCA carriers: No difference in the rate of local recurrence between BRCA carriers & non-carriers. Chemo & postmastectomy RT were assoc. with ⬇️ local recurrence rates.
#hereditarycancer #bcsm #oncsky #cancerresearch
#hereditarycancer #bcsm #oncsky #cancerresearch
Breast cancer outcomes after skin- and nipple-sparing mastectomy in BRCA pathogenic mutation carriers versus non-BRCA carriers
More than two decades ago, several randomised controlled trials demonstrated the non-inferior
survival after breast conservation surgery (BCS) and radiation therapy (RT), (BCS
with RT is regarded as b...
www.thegreenjournal.com
January 28, 2025 at 4:55 PM
#Breastcancer outcomes after NSM in #BRCA pathogenic mutation carriers vs. non-BRCA carriers: No difference in the rate of local recurrence between BRCA carriers & non-carriers. Chemo & postmastectomy RT were assoc. with ⬇️ local recurrence rates.
#hereditarycancer #bcsm #oncsky #cancerresearch
#hereditarycancer #bcsm #oncsky #cancerresearch
Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in breast cancer: population-based study
➡️ doi.org/10.1093/bjso...
@bjsacademy.bsky.social
@bjsurgery.bsky.social
➡️ doi.org/10.1093/bjso...
@bjsacademy.bsky.social
@bjsurgery.bsky.social
Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in breast cancer: population-based study
Postmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast reconstruction in patients with breast cancer, and the sentinel lymph node (SLN)
doi.org
May 1, 2025 at 10:05 AM
Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in breast cancer: population-based study
➡️ doi.org/10.1093/bjso...
@bjsacademy.bsky.social
@bjsurgery.bsky.social
➡️ doi.org/10.1093/bjso...
@bjsacademy.bsky.social
@bjsurgery.bsky.social
📰 New in NEJM: Long-term results from the #SUPREMOtrial (BIG 2-04) show when postmastectomy radiotherapy may be safely avoided in “intermediate-risk” #breastcancer patients. A major step toward more tailored, less toxic treatment. www.nejm.org/doi/full/10....
November 7, 2025 at 1:47 PM
📰 New in NEJM: Long-term results from the #SUPREMOtrial (BIG 2-04) show when postmastectomy radiotherapy may be safely avoided in “intermediate-risk” #breastcancer patients. A major step toward more tailored, less toxic treatment. www.nejm.org/doi/full/10....
🚨New in #Oncology!
Phase 3 Trial Results:
📊 Omitting postmastectomy chest-wall irradiation in intermediate-risk breast cancer patients showed no significant difference in 10-year OS, compared to those who received radiation.
💡 Findings shed new light on treatment de-escalation after mastectomy.
Phase 3 Trial Results:
📊 Omitting postmastectomy chest-wall irradiation in intermediate-risk breast cancer patients showed no significant difference in 10-year OS, compared to those who received radiation.
💡 Findings shed new light on treatment de-escalation after mastectomy.
November 6, 2025 at 12:30 PM
🚨New in #Oncology!
Phase 3 Trial Results:
📊 Omitting postmastectomy chest-wall irradiation in intermediate-risk breast cancer patients showed no significant difference in 10-year OS, compared to those who received radiation.
💡 Findings shed new light on treatment de-escalation after mastectomy.
Phase 3 Trial Results:
📊 Omitting postmastectomy chest-wall irradiation in intermediate-risk breast cancer patients showed no significant difference in 10-year OS, compared to those who received radiation.
💡 Findings shed new light on treatment de-escalation after mastectomy.
📢 New Guideline Alert:
🩺 ASTRO-ASCO-SSO release updated clinical practice guideline on Postmastectomy Radiation Therapy (PMRT) in breast cancer
Key updates:
🔹 Indications for PMRT after surgery & neoadjuvant therapy
🔹 Guidance on target volumes, dosing & techniques
🔗 bit.ly/ONCOnews17S-1
🩺 ASTRO-ASCO-SSO release updated clinical practice guideline on Postmastectomy Radiation Therapy (PMRT) in breast cancer
Key updates:
🔹 Indications for PMRT after surgery & neoadjuvant therapy
🔹 Guidance on target volumes, dosing & techniques
🔗 bit.ly/ONCOnews17S-1
September 17, 2025 at 10:30 AM
📢 New Guideline Alert:
🩺 ASTRO-ASCO-SSO release updated clinical practice guideline on Postmastectomy Radiation Therapy (PMRT) in breast cancer
Key updates:
🔹 Indications for PMRT after surgery & neoadjuvant therapy
🔹 Guidance on target volumes, dosing & techniques
🔗 bit.ly/ONCOnews17S-1
🩺 ASTRO-ASCO-SSO release updated clinical practice guideline on Postmastectomy Radiation Therapy (PMRT) in breast cancer
Key updates:
🔹 Indications for PMRT after surgery & neoadjuvant therapy
🔹 Guidance on target volumes, dosing & techniques
🔗 bit.ly/ONCOnews17S-1
Earlier this week, ASCO, @astro-org.bsky.social & @socsurgonc.bsky.social released a guideline with new recommendations for postmastectomy RT for patients with #breastcancer. #ASCODailyNews has more, including interviews with members of the joint task force: brnw.ch/21wVTiX
September 18, 2025 at 5:24 PM
Earlier this week, ASCO, @astro-org.bsky.social & @socsurgonc.bsky.social released a guideline with new recommendations for postmastectomy RT for patients with #breastcancer. #ASCODailyNews has more, including interviews with members of the joint task force: brnw.ch/21wVTiX
Postmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast reconstruction in patients with breast cancer, and the sentinel lymph node (SLN) status is crucial in evaluating the need for PMRT.
May 1, 2025 at 10:05 AM
Postmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast reconstruction in patients with breast cancer, and the sentinel lymph node (SLN) status is crucial in evaluating the need for PMRT.
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in #BreastCancer. www.nejm.org/doi/full/10....
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer | NEJM
The role of postmastectomy chest-wall irradiation in patients with breast cancer classified
as pN1 (with involvement of one to three axillary nodes) or pN0 (pathologically node
negative) with addit...
www.nejm.org
November 7, 2025 at 10:23 AM
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in #BreastCancer. www.nejm.org/doi/full/10....
#SABCS24 #bcsm #OncSky #RadOnc #MedSky
BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence)
@oncoalert.bsky.social
BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence)
@oncoalert.bsky.social
December 12, 2024 at 4:23 PM
#SABCS24 #bcsm #OncSky #RadOnc #MedSky
BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence)
@oncoalert.bsky.social
BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence)
@oncoalert.bsky.social
In intermediate-risk breast cancer, postmastectomy chest-wall irradiation did not improve 10-year overall survival as compared with no chest-wall irradiation. Full SUPREMO phase 3 trial results: nej.md/3Jxd3sI
#MedSky #Oncology
#MedSky #Oncology
November 5, 2025 at 10:08 PM
In intermediate-risk breast cancer, postmastectomy chest-wall irradiation did not improve 10-year overall survival as compared with no chest-wall irradiation. Full SUPREMO phase 3 trial results: nej.md/3Jxd3sI
#MedSky #Oncology
#MedSky #Oncology
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival
https://www.europesays.com/ie/166770/
Findings from the international phase 3 SUPREMO trial (ISRCTN61145589) are reshaping how clinicians approach postmastectomy treatment for patients…
https://www.europesays.com/ie/166770/
Findings from the international phase 3 SUPREMO trial (ISRCTN61145589) are reshaping how clinicians approach postmastectomy treatment for patients…
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival - Ireland
Findings from the international phase 3 SUPREMO trial (ISRCTN61145589) are reshaping how clinicians approach postmastectomy treatment for patients with
www.europesays.com
November 6, 2025 at 10:30 PM
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival
https://www.europesays.com/ie/166770/
Findings from the international phase 3 SUPREMO trial (ISRCTN61145589) are reshaping how clinicians approach postmastectomy treatment for patients…
https://www.europesays.com/ie/166770/
Findings from the international phase 3 SUPREMO trial (ISRCTN61145589) are reshaping how clinicians approach postmastectomy treatment for patients…
Implant-based reconstruction linked to increased risk of breast lymphomas
Credit: Unsplash/CC0 Public Domain Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell…
Credit: Unsplash/CC0 Public Domain Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell…
Implant-based reconstruction linked to increased risk of breast lymphomas
Credit: Unsplash/CC0 Public Domain Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell non-Hodgkin lymphoma histologies. Previous work has described an increase in anaplastic large-cell lymphomas in association with breast implants. Adverse events resulted in a black-box warning by the US Food and Drug Administration on all breast implants.
todayheadline.co
August 15, 2025 at 11:10 AM
Implant-based reconstruction linked to increased risk of breast lymphomas
Credit: Unsplash/CC0 Public Domain Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell…
Credit: Unsplash/CC0 Public Domain Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell…